Zeposia

cognitive function

Early Ozanimod Treatment Linked With Improved Cognition in MS

Early use of ozanimod (Zeposia®) was found to improve or preserve cognitive function in patients with relapsing multiple sclerosis (MS), according to a new post hoc analysis from the phase 3 SUNBEAM trial (NCT02294058) and the phase 3 open-label extension (OLE) DAYBREAK trial (NCT02576717). The analysis showed that the greatest treatment effect was observed in…

Disease-Modifying Therapies Could Help Protect Patients With MS From COVID-19

Patients with multiple sclerosis (MS) treated with interferon beta-1a (IFN) demonstrated significantly increased humoral responses to the Pfizer mRNA vaccine for COVID-19, according to new study results published in Multiple Sclerosis and Related Disorders. In contrast, patients with MS taking cladribine (CLAD), fingolimod (FTY), and ocrelizumab (OCRE) showed a weakened humoral response. Patients on CLAD,…

Next post in MS News Briefs